Evidence map›Paper›PMID 35579066›Full record

ArticleClinical trials (London, England)2022

Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently.

Ian R White, Babak Choodari-Oskooei, Matthew R Sydes, Brennan C Kahan, Leanne McCabe, Anna Turkova, Hanif Esmail, Diana M Gibb, Deborah Ford

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Towards primary prevention of multiple sclerosis.Nature reviews. Neurology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ian R WhiteMRC Clinical Trials Unit at UCL, London, UK.ORCID 0000-0002-6718-7661
Babak Choodari-OskooeiMRC Clinical Trials Unit at UCL, London, UK.ORCID 0000-0001-7679-5899
Matthew R SydesMRC Clinical Trials Unit at UCL, London, UK.ORCID 0000-0002-9323-1371
Brennan C KahanMRC Clinical Trials Unit at UCL, London, UK.ORCID 0000-0001-9957-0844
Leanne McCabeMRC Clinical Trials Unit at UCL, London, UK.
Anna TurkovaMRC Clinical Trials Unit at UCL, London, UK.
Hanif EsmailMRC Clinical Trials Unit at UCL, London, UK.
Diana M GibbMRC Clinical Trials Unit at UCL, London, UK.
Deborah FordMRC Clinical Trials Unit at UCL, London, UK.

Funding

Medical Research Council MC_UU_00004/03Medical Research Council MC_UU_00004/04Medical Research Council MC_UU_00004/09Medical Research Council MC_UU_12023/29
6 · The paper itself

Abstract

backgroundFactorial designs and multi-arm multi-stage (MAMS) platform designs have many advantages, but the practical advantages and disadvantages of combining the two designs have not been explored.

methodsWe propose practical methods for a combined design within the platform trial paradigm where some interventions are not expected to interact and could be given together.

resultsWe describe the combined design and suggest diagrams that can be used to represent it. Many properties are common both to standard factorial designs, including the need to consider interactions between interventions and the impact of intervention efficacy on power of other comparisons, and to standard multi-arm multi-stage designs, including the need to pre-specify procedures for starting and stopping intervention comparisons. We also identify some specific features of the factorial-MAMS design: timing of interim and final analyses should be determined by calendar time or total observed events; some non-factorial modifications may be useful; eligibility criteria should be broad enough to include any patient eligible for any part of the randomisation; stratified randomisation may conveniently be performed sequentially; and analysis requires special care to use only concurrent controls.

conclusionA combined factorial-MAMS design can combine the efficiencies of factorial trials and multi-arm multi-stage platform trials. It allows us to address multiple research questions under one protocol and to test multiple new treatment options, which is particularly important when facing a new emergent infection such as COVID-19.

Indexed as

Clinical Trials as TopicResearch DesignAdaptive Clinical Trials as TopicHumansRandom Allocationadaptive trial designsfactorial trialmulti-arm multi-stagePlatform trials

Identifiers

PMID35579066
PMCPMC9373200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.